Navigation Links
New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation
Date:12/7/2008

SAN FRANCISCO, Dec. 7 /PRNewswire-FirstCall/ -- Patients with non-valvular atrial fibrillation receiving either 30 mg or 60 mg once-daily dose of DU-176b, an investigational oral Factor Xa inhibitor, experienced comparable safety and tolerability compared to those taking warfarin, according to new Phase II data presented today at the 50th Annual Meeting of the American Society of Hematology in San Francisco. These findings are the first results from a Phase II clinical study evaluating an oral Factor Xa inhibitor in atrial fibrillation patients. DU-176b is being developed solely by Daiichi Sankyo Company, Limited (TSE: 4568).

The objective of the multinational study was to assess the safety of four dose regimens of DU-176b in patients with non-valvular atrial fibrillation (AF), as compared to warfarin. While the incidence of major and clinically relevant non-major bleeding events was significantly higher in the twice-daily DU-176b treatment groups (30 mg or 60 mg twice per day), compared with warfarin, the incidence reported in the once-daily DU-176b treatment groups (30 mg or 60 mg once per day) was similar to that in the warfarin-treated patient group. Bleeding events were evaluated using guidelines established by the International Society on Thrombosis and Haemostasis(1), the most sensitive scale of those currently used in clinical studies in cardiovascular disease.

"These results are noteworthy and encouraging because we observed significantly fewer adverse bleeding events in patients receiving one dose of DU-176b per day, versus two doses per day, suggesting with this compound, the most convenient dosing regimens also appear to be safer," said Jeffrey I. Weitz, MD, FACP, FRCP, professor of medicine and biochemistry, McMaster University and director, Henderson Research Centre, Hamilton, Ontario. "These data provide insight into the optimal dosing regimens for Phase III studies of DU-176b."


'/>"/>
SOURCE Daiichi Sankyo Company, Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... -- Smile Train and its technology partner BioDigital have been ... among leading global health innovations in The Hive at ... Washington, D.C. at The John F. Kennedy ... Train is honored to be represented through our partnership ... health and medicine that TEDMED unites each year," said ...
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Full ... as the new Vice President of Business Development. ... 30 years in a number of different business development ... industry. These positions were primarily related to business development/sales ... the past 30 years makes him a key and ...
(Date:7/25/2014)... , July 25, 2014 GrowBLOX Sciences, Inc. (OTCQB: ... Memorandum of Understanding ("MOU") with LaurelCo, LLC, an ... acquisition of both cultivation and dispensary medical marijuana licenses in ... the MOU, GBLX will acquire a 20% equity interest in ... GrowBLOX TM growing chambers, as well as all technology ...
Breaking Medicine Technology:Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3Contract Research Organization WCCT Global Welcomes Peter Nieto as Vice President of Business Development 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3
... 8, 2012  Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX ... and commercialization of medically important pharmaceutical products for the ... results for the first quarter ended March 31, 2012. ... cash, cash equivalents, interest receivable, and investment securities of ...
... of scientists led by Dr. Stanley Fricke of the Children,s ... imaging (MRI) sound barrier," a finding that could lead to ... clinical study published this week in the peer-reviewed journal ... said Dr. Fricke, "is to image small children in seconds ...
Cached Medicine Technology:Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results 2Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results 3Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results 4Children's National Medical Center Breaks MRI Speed Sound Barrier 2
(Date:7/26/2014)... Another DePuy Pinnacle hip lawsuit against Johnson ... filed by Wright & Schulte LLC. This DePuy ... an Erie County, Ohio man who alleges that he has ... since receiving his Pinnacle Hip implant in 2008. According to ... to undergo a complex and risky revision surgery to replace ...
(Date:7/26/2014)... According to the Banish My Bumps Pdf review ... that covers detailed instructions on how to eliminate ... any medication. , Vkool reveals in its review ... for relieving symptoms of keratosis pilaris quickly. In addition, ...     How to treat children's keratosis pilaris ,     How ...
(Date:7/26/2014)... July 26, 2014 The birth control ... Mirena IUD contraceptive of new legal information on the ... showing the number of lawsuits pending for July alleging ... free resource for those using popular prescription drugs and ... recalls, studies and legal news all in one place, ...
(Date:7/25/2014)... 26, 2014 2014 Deep ... Permeation Chromatography Industry” is a professional and ... China Gel Permeation Chromatography market. The report ... Gel Permeation Chromatography definition, classification, application, and ... overview. This research covers the international market ...
(Date:7/25/2014)... According to a new market research report ... thermography, ultrasound emission, lubricating oil analysis, corrosion monitoring, ... - Global Forecast to 2014 - 2020", published ... expected to reach $2.50 at a CAGR of ... market data Tables and 57 Figures spread through ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Recipient Who Faces Surgery To Replace Artificial Hip Implant 5Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 2Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 3Health News:DrugNews Adds Latest Court Updates on Mirena IUD Lawsuits 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 2Health News:2014 China & Global GPC Industry - Gel Permeation Chromatography Development Trends Now at DeepResearchReports.com 3Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 4
... The U.S. Military has selected iCRco, an American CR Company, as ... portable, fast and efficient diagnoses for our troops injured in battle. ... ... Military has selected iCRco, an American CR Company, as its new ...
... to Host Investor Conference Call on Monday, August 11, 2008 at 8:30am ... ... YORK, Aug. 8 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ), a biopharmaceutical ... for the treatment of life-threatening,diseases, including renal disease and cancer, today announced ...
... YORK, Aug. 8 Mergent, Inc., administrator ... underlying indexes for the,HealthShares Exchange Traded Funds, ... opening of trading on Monday August 11, ... Co. (Tokyo, Japan: 4518) in the,HealthShares(TM) Infectious ...
... MEDQ ) the largest Medical Transcription Service Organization,(MTSO) in ... ended June,30, 2008. Revenue for the second quarter of ... second quarter of 2007. The decrease in revenue,of $6.2 ... primarily due to,customer losses experienced during the second half ...
... Fairbanks campus will be home to the Eighth Conference ... conference is organized in cooperation with the Standing Committee ... international participants to address issues of importance to Arctic ... , More than150 guests are expected to attend at ...
... is available in French . , Montreal, ... patients who receive early treatment for Hepatitis C virus ... a rapid poly-functional immune response against HCV similar to ... study published in the Journal of Virology . ...
Cached Medicine News:Health News:US Military Chooses American Made iCRco Digital Radiography Systems 2Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 2Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 3Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 4Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 5Health News:Mergent, Inc. Announces Changes to the HealthShares(TM) Infectious Disease and HealthShares(TM) Composite Indexes 2Health News:MedQuist Reports Second Quarter 2008 Results 2Health News:MedQuist Reports Second Quarter 2008 Results 3Health News:MedQuist Reports Second Quarter 2008 Results 4Health News:MedQuist Reports Second Quarter 2008 Results 5Health News:MedQuist Reports Second Quarter 2008 Results 6Health News:MedQuist Reports Second Quarter 2008 Results 7Health News:MedQuist Reports Second Quarter 2008 Results 8Health News:MedQuist Reports Second Quarter 2008 Results 9Health News:UAF to host Eighth Conference of Arctic Parliamentarians 2Health News:Early treatment is key to combating hepatitis C virus 2
Rapid Immunoassay for the detection of Respiratory Syncytial Virus....
Anti-Rotavirus Antigen Assay (ELISA)....
A direct enzyme immunoassay for detection of gr. A rotavirus in fecal specimens....
... Acolytes core technology relates to the ... enzyme found in all living cells. ... measured using bioluminescence. By coupling ... example via extraction using antibody-coated beads, Acolyte ...
Medicine Products: